AxoGen Posts Strong Growth and Raises Capital With Offering

AxoGen ( (AXGN) ) just unveiled an update.

Axogen on February 24, 2026 reported that fourth-quarter 2025 revenue rose 21.3% year over year to $59.9 million and full-year revenue grew 20.2% to $225.2 million, driven by double-digit gains across extremities, oral maxillofacial and head and neck, and breast markets. Despite a GAAP net loss of $13.2 million in the quarter and $15.7 million for the year, the company maintained flat adjusted net income of $3.5 million for the quarter, expanded full-year adjusted net income to $14.4 million and adjusted EBITDA to $27.9 million, and increased year-end cash and investments to $45.5 million.

Profitability metrics were temporarily pressured by approximately $1.9 million of largely non-cash, one-time costs tied to the U.S. FDA’s December 3, 2025 approval of the Biologics License Application for Avance, now the only implantable biologic indicated for peripheral nerve discontinuities. Axogen further strengthened its balance sheet with a January 23, 2026 upsized equity offering that generated $133.3 million in net proceeds, enabling full repayment of its Oberland loan facility and leaving additional capital for general corporate use, while expanded payer coverage and new CMS procedure coding enhanced reimbursement and reinforced its competitive position in peripheral nerve repair.

The most recent analyst rating on (AXGN) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on AxoGen stock, see the AXGN Stock Forecast page.

Spark’s Take on AXGN Stock

According to Spark, TipRanks’ AI Analyst, AXGN is a Neutral.

The score is held back most by weaker financial quality (still near breakeven profitability and deteriorating free cash flow) and unattractive earnings-based valuation (negative P/E). Offsetting these, technicals are moderately constructive, and the latest earnings call and corporate updates point to accelerating revenue growth, improving operating leverage, and a meaningful regulatory milestone—tempered by dilution and execution/regulatory timing risks.

To see Spark’s full report on AXGN stock, click here.

More about AxoGen

Axogen, Inc. is a medical technology company focused on the science, development and commercialization of surgical solutions for peripheral nerve regeneration and repair. Its portfolio, led by Avance acellular nerve allograft and supported by Axoguard nerve repair products and Avive+ Soft Tissue Matrix, targets surgeons and healthcare providers treating traumatic peripheral nerve injuries across extremities, oral maxillofacial, head and neck, and breast procedures.

The company positions itself as a leader in peripheral nerve restoration, aiming to make restoration of nerve function an expected standard of care. By expanding clinically proven, economically effective repair options and driving broader reimbursement and coverage, Axogen seeks to improve patient quality of life while deepening penetration in its targeted reconstructive and nerve repair markets.

Average Trading Volume: 942,940

Technical Sentiment Signal: Buy

Current Market Cap: $1.77B

Learn more about AXGN stock on TipRanks’ Stock Analysis page.